Dr Ednah Ooko
Principal Investigator
Collaborations
Videos
Bio
She attained her PhD in Mainz Germany in 2017 where she was understanding the genomics of multidrug resistance in a broad spectrum of cancer cells. The role of P-glycoprotein was key to this understanding. This was then followed by a postdoctoral experience at the National Institute of Health, National Cancer Institute, Bethesda Maryland, USA where she worked on the CRISPAR techniques in understanding multidrug resistance genomics in ovarian, uterine and Breast cancer. She is currently at Early research fellow working on antimicrobial resistance (AMR) in Kilifi Kenya where she is focusing on bacterial genomics and the role of the microbiome in carriage of ESBL-Es. To this point the gruop focusses on community acquired and carriage of ESBL-E and as of now are on the early phases of the research.
See moreCurrent Work
The team hopes to clearly document the evolution of AMR in Kenya and give a clear position on where we are on AMR currently including the resistance markers circulating in our community and which drugs we can apply to avoid or reduce the problem of antibiotic drug resistance.
Recent publications
The CINAMR (Clinical Information Network-Antimicrobial Resistance) Project: A pilot microbial surveillance using hospitals linked to regional laboratories in Kenya: Study Protocol.
Akech, S., Nyamwaya, B., Gachoki, J., Ogero, M., Kigo, J., Maina, M., Mutua, E., Ooko, E., Bejon, P., Mwarumba, S., Bahati, F., Mvera, B., Musyimi, R., Onsare, R., Hutter, J., Tanui, E., Wesangula, E., Turner, P., Dunachie, S., Lucey, O., McKnight, J.
Wellcome Open Res, (2022). 7:256
Dr Ednah Ooko
Principal Investigator
Biography
She attained her PhD in Mainz Germany in 2017 where she was understanding the genomics of multidrug resistance in a broad spectrum of cancer cells. The role of P-glycoprotein was key to this understanding. This was then followed by a postdoctoral experience at the National Institute of Health, National Cancer Institute, Bethesda Maryland, USA where she worked on the CRISPAR techniques in understanding multidrug resistance genomics in ovarian, uterine and Breast cancer. She is currently at Early research fellow working on antimicrobial resistance (AMR) in Kilifi Kenya where she is focusing on bacterial genomics and the role of the microbiome in carriage of ESBL-Es. To this point the gruop focusses on community acquired and carriage of ESBL-E and as of now are on the early phases of the research.
See moreCurrent Work
The team hopes to clearly document the evolution of AMR in Kenya and give a clear position on where we are on AMR currently including the resistance markers circulating in our community and which drugs we can apply to avoid or reduce the problem of antibiotic drug resistance.
Collaborations
Project Research
No active details yet
Videos
The CINAMR (Clinical Information Network-Antimicrobial Resistance) Project: A pilot microbial surveillance using hospitals linked to regional laboratories in Kenya: Study Protocol.
Akech, S., Nyamwaya, B., Gachoki, J., Ogero, M., Kigo, J., Maina, M., Mutua, E., Ooko, E., Bejon, P., Mwarumba, S., Bahati, F., Mvera, B., Musyimi, R., Onsare, R., Hutter, J., Tanui, E., Wesangula, E., Turner, P., Dunachie, S., Lucey, O., McKnight, J.
Wellcome Open Res, (2022). 7:256
Dr Ednah Ooko 9
Principal Investigator
Biography
She attained her PhD in Mainz Germany in 2017 where she was understanding the genomics of multidrug resistance in a broad spectrum of cancer cells. The role of P-glycoprotein was key to this understanding. This was then followed by a postdoctoral experience at the National Institute of Health, National Cancer Institute, Bethesda Maryland, USA where she worked on the CRISPAR techniques in understanding multidrug resistance genomics in ovarian, uterine and Breast cancer. She is currently at Early research fellow working on antimicrobial resistance (AMR) in Kilifi Kenya where she is focusing on bacterial genomics and the role of the microbiome in carriage of ESBL-Es. To this point the gruop focusses on community acquired and carriage of ESBL-E and as of now are on the early phases of the research.